Social Behavior
Gilead Sciences Strikes Deal with Merus for Trispecific Antibody Development
Gilead Sciences, Merus NV, Trispecific antibodies, T-Cell engager collaboration, Cancer therapy innovation
Biden Proposes Expansion of Medicare Drug Price Negotiation Program
Biden, Medicare, Drug Prices, Negotiation, Increased Scrutiny, More Drugs, Health Care Policy
Merck KGaA Bolsters Protein Degradation Pipeline with $756M C4 Therapeutics Partnership
Merck KGaA, C4 Therapeutics, Targeted Protein Degradation, Collaboration, $756M Deal, Oncogenic Proteins, TORPEDO® Platform, Mid-Single to Low-Double Digit Tiered Royalties, Upfront Payment: $16 Million, Potential Milestone Payments: Up to $740 Million
AstraZeneca Abandons Roxadustat’s US Future while Retaining Collaboration with FibroGen in China
FibroGen, roxadustat, China, Ultrasonography, AstraZeneca, Collaboration, chemotherapy-induced anemia, Retained
Sanofi and Denali’s ALS Candidate SAR443820 Fails Phase 2 Trial
Amyotrophic Lateral Sclerosis, sanofi, SAR443820, Denali, Collaboration, Denali’s
Kyowa Kirin Partners with BridgeBio for Potential Achondroplasia Drug, Pays $100M in Pivotal Collaboration
Achondroplasia, infigratinib, BridgeBio, Kyowa, Kirin, Collaboration
Jazz Pharmaceuticals Expands Oncology Pipeline with Redx’s KRAS Inhibitor Program
Kirsten murine sarcoma virus, Jazz, Redx, Inhibitor
GSK confirms Arexvy is a blockbuster but says the RSV battle has just begun
Arexvy, Respiratory syncytial virus, battle, begun
Promising Vertex Pain Med Points to New Era for Analgesics
historical period, Analgesics, Opioid, VX-548, Analgesics, Effectiveness, aspects of adverse effects
Lilly’s Donanemab Poised for FDA Decision amid Embraced Alzheimer’s Disease Competition
Alzheimer’s Disease, Donanemab, United States Food and Drug Administration, Lilly’s